Drug Profile


Alternative Names: SAGE-547; SGE-102

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator Sage Therapeutics
  • Developer SAGE Therapeutics
  • Class Antidepressants; Antiepileptic drugs; Small molecules; Steroids
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Status epilepticus
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Postnatal depression; Status epilepticus
  • Phase II Essential tremor
  • Preclinical Major depressive disorder

Most Recent Events

  • 22 Apr 2017 Pharmacokinetics data from a phase I/II trial in super-refractory Status epilepticus presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 07 Mar 2017 Chemical structure information added
  • 19 Dec 2016 Phase-III clinical trials in Postnatal depression (IV) before December
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top